NewEdge Advisors LLC Acquires 11,414 Shares of Becton, Dickinson and Company $BDX

NewEdge Advisors LLC increased its stake in shares of Becton, Dickinson and Company (NYSE:BDX – Free Report) by 35.0% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 44,032 shares of the medical instruments supplier’s stock after purchasing an additional 11,414 shares during the quarter. NewEdge Advisors LLC’s holdings in Becton, Dickinson and Company were worth $6,923,000 at the end of the most recent reporting period.

Other institutional investors also recently modified their holdings of the company. Imprint Wealth LLC bought a new stake in Becton, Dickinson and Company in the third quarter valued at approximately $25,000. Steph & Co. increased its holdings in Becton, Dickinson and Company by 95.6% in the fourth quarter. Steph & Co. now owns 133 shares of the medical instruments supplier’s stock worth $26,000 after purchasing an additional 65 shares in the last quarter. SHP Wealth Management bought a new position in shares of Becton, Dickinson and Company during the 4th quarter worth approximately $26,000. Prosperity Bancshares Inc acquired a new position in shares of Becton, Dickinson and Company during the fourth quarter valued at about $29,000. Finally, WPG Advisers LLC increased its position in Becton, Dickinson and Company by 64.2% in the 4th quarter. WPG Advisers LLC now owns 156 shares of the medical instruments supplier’s stock valued at $30,000 after buying an additional 61 shares in the last quarter. 86.97% of the stock is currently owned by institutional investors and hedge funds.

Get Becton Dickinson and Company alerts:

Insider Activity at Becton, Dickinson and Company

In related news, EVP Michael David Garrison sold 1,100 shares of the stock in a transaction that occurred on Wednesday, June 24th. The shares were sold at an average price of $145.66, for a total transaction of $160,226.00. Following the transaction, the executive vice president owned 13,172 shares in the company, valued at $1,918,633.52. This represents a 7.71% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Thomas E. Polen, Jr. sold 2,764 shares of Becton, Dickinson and Company stock in a transaction that occurred on Monday, June 1st. The stock was sold at an average price of $146.35, for a total transaction of $404,511.40. Following the completion of the sale, the chief executive officer directly owned 110,163 shares of the company’s stock, valued at approximately $16,122,355.05. This trade represents a 2.45% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 5,189 shares of company stock valued at $765,661 over the last three months. 0.40% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

BDX has been the subject of several research reports. Wells Fargo & Company lifted their price target on shares of Becton, Dickinson and Company from $161.00 to $170.00 and gave the company an “equal weight” rating in a research report on Friday. Jefferies Financial Group reissued a “buy” rating and set a $210.00 price objective on shares of Becton, Dickinson and Company in a report on Thursday. Citigroup raised their target price on Becton, Dickinson and Company from $198.00 to $204.00 and gave the stock a “buy” rating in a research note on Friday. The Goldman Sachs Group reduced their target price on Becton, Dickinson and Company from $156.00 to $150.00 and set a “neutral” rating for the company in a report on Wednesday, May 27th. Finally, TD Cowen increased their price target on shares of Becton, Dickinson and Company from $163.00 to $182.00 and gave the stock a “hold” rating in a report on Wednesday, August 5th. Eight research analysts have rated the stock with a Buy rating, eight have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus target price of $185.00.

View Our Latest Stock Report on BDX

Becton, Dickinson and Company Trading Up 1.5%

NYSE:BDX opened at $179.57 on Tuesday. The stock has a market cap of $49.48 billion, a price-to-earnings ratio of 54.09, a PEG ratio of 12.47 and a beta of 0.19. The company has a quick ratio of 0.51, a current ratio of 0.87 and a debt-to-equity ratio of 0.55. The company’s 50 day moving average price is $155.05 and its 200-day moving average price is $162.03. Becton, Dickinson and Company has a 52 week low of $127.59 and a 52 week high of $187.35.

Becton, Dickinson and Company (NYSE:BDX – Get Free Report) last released its quarterly earnings data on Thursday, August 6th. The medical instruments supplier reported $3.23 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.14 by $0.09. The business had revenue of $4.98 billion for the quarter, compared to analysts’ expectations of $4.89 billion. Becton, Dickinson and Company had a return on equity of 14.84% and a net margin of 4.52%.The firm’s quarterly revenue was up 5.4% on a year-over-year basis. During the same period in the prior year, the firm posted $3.68 EPS. Becton, Dickinson and Company has set its FY 2026 guidance at 12.620-12.720 EPS. On average, equities research analysts forecast that Becton, Dickinson and Company will post 12.67 earnings per share for the current fiscal year.

Becton, Dickinson and Company Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Wednesday, September 30th. Stockholders of record on Wednesday, September 9th will be paid a $1.05 dividend. The ex-dividend date is Wednesday, September 9th. This represents a $4.20 dividend on an annualized basis and a dividend yield of 2.3%. Becton, Dickinson and Company’s payout ratio is currently 126.51%.

Becton, Dickinson and Company Company Profile

(Free Report)

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.

Featured Articles

• Five stocks we like better than Becton, Dickinson and Company
• SoundHound AI Sends a Loud Signal After Its Q2 Earnings Beat
• 3 Dividend Champion Utilities for a Market That Can’t Sit Still
• These 3 Most-Upgraded Stocks Have Almost Nothing to Do With AI
• First Solar’s Profit Engine Faces a New Policy Test in Washington

Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton, Dickinson and Company (NYSE:BDX – Free Report).

Receive News & Ratings for Becton Dickinson and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and Company and related companies with MarketBeat.com's FREE daily email newsletter.